Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002316715 | SCV000850373 | uncertain significance | Inborn genetic diseases | 2021-09-30 | criteria provided, single submitter | clinical testing | The c.4431A>T (p.L1477F) alteration is located in exon 29 (coding exon 28) of the VPS13B gene. This alteration results from a A to T substitution at nucleotide position 4431, causing the leucine (L) at amino acid position 1477 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV001372513 | SCV001569182 | uncertain significance | Cohen syndrome | 2022-03-14 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 1477 of the VPS13B protein (p.Leu1477Phe). This variant is present in population databases (rs61754112, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with VPS13B-related conditions. ClinVar contains an entry for this variant (Variation ID: 589484). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001372513 | SCV002082543 | uncertain significance | Cohen syndrome | 2019-11-11 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003945760 | SCV004763473 | uncertain significance | VPS13B-related disorder | 2024-02-27 | no assertion criteria provided | clinical testing | The VPS13B c.4356A>T variant is predicted to result in the amino acid substitution p.Leu1452Phe. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0053% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |